Intetumumab
Appearance
Monoclonal antibody | |
---|---|
Type | Whole antibody |
Source | Human |
Target | integrin alpha-V |
Clinical data | |
ATC code |
|
Identifiers | |
CAS Number | |
ChemSpider |
|
UNII | |
KEGG | |
Chemical and physical data | |
Formula | C6468H10008N1744O2006S40 |
Molar mass | 145.6 kg/mol g·mol−1 |
(what is this?) (verify) |
Intetumumab is a human monoclonal antibody that was being studied for the treatment of solid tumors.[1]
Intetumumab was developed by Centocor, Inc.
Phase II clinical trials for treatment of melanoma and prostate cancer were in progress when development of the drug was discontinued.[2]
References
- ^ "Statement On A Nonproprietary Name Adopted By The USAN Council: Intetumumab" (PDF). American Medical Association.
- ^ "Intetumumab". AdisInsight. Retrieved 30 January 2017.